Sahaj Rathi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sahaj Rathi has a total of 204 co-authors. Here are the top co-authors by number of shared publications:
- Radha Krishan Dhiman
Department of Hepatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
19 shared publications - Sunil Taneja
Department of Hepatology, Postgraduate Institute of Medical Education & Research, Chandigarh, India
15 shared publications - Ajay Duseja
Department of Hepatology, PGIMER, Chandigarh, India
14 shared publications Radha K. Dhiman
Department of Hepatology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
13 shared publications- Arka De
Department of Hepatology, PGIMER, Chandigarh, India
11 shared publications - Madhumita Premkumar
Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
9 shared publications
Latest Publications
- 24 January 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (7) , 1-10
Rifaximin Improves Frailty in Patients with Decompensated Cirrhosis: A Randomized Trial
Background Patients with decompensated cirrhosis have high prevalence of frailty that increases morbidity and mortality. This study was done to determine the impact of six months of Rifaximin therapy on frailty in patients with decompensated cirrhosis. Methods 100 patients with frailty as assessed by Liver frailty Index (LFI > 4.5) at baseline were randomized 1:1 to receive standard medical therapy (SMT) plus Rifaximin (rSMT, intervention) versus SMT (control) alone. The primary outcome was an improvement in frailty at 6 months. Secondary outcome measures included improvement in CTP and MELD, inflammatory markers, hospitalization, and survival. Results Frailty improved significantly in the intervention arm as compared to the control arm (4.7(4.5–5.0) to 4.2(4.1–4.5), (P < 0.00) vs 4.7(4.6–5.0) to 4.7(4.4–5.2), (P = 0.70) at 6 months. The disease severity as assessed by CTP and MELD, scores showed a significant improvement in the rSMT group as compared to the SMT group (P < 0.05). The delta change in MELD score was −2.3 ± 2.9 versus 1.7 ± 5.4 (P < 0.00) in the intervention arm as compared to control arm. Inflammatory markers showed significant improvement, with a higher delta change in IL-6 in the intervention arm (-10 [-15.7/-4.4] vs -5 [-10.2/-0.5]; P = 0.01). The patients in rSMT arm had lesser number of hospitalizations 8(16%) vs 26(52%); P < 0.00) over the course of 6 months. The mortality in rSMT and SMT arms was 10% (n = 5), and 22% (n = 11), respectively though there was no significant difference in the overall survival (P = 0.11). Conclusion Rifaximin therapy in decompensated cirrhosis has a significant impact on improving frailty and disease severity, with a reduction in hospitalization rate. Clinical Trial Registry Number CTRI/2023/01/048824 Graphical Abstract
- 24 January 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (7) , 1-10
Rifaximin Improves Frailty in Patients with Decompensated Cirrhosis: A Randomized Trial
Background Patients with decompensated cirrhosis have high prevalence of frailty that increases morbidity and mortality. This study was done to determine the impact of six months of Rifaximin therapy on frailty in patients with decompensated cirrhosis. Methods 100 patients with frailty as assessed by Liver frailty Index (LFI > 4.5) at baseline were randomized 1:1 to receive standard medical therapy (SMT) plus Rifaximin (rSMT, intervention) versus SMT (control) alone. The primary outcome was an improvement in frailty at 6 months. Secondary outcome measures included improvement in CTP and MELD, inflammatory markers, hospitalization, and survival. Results Frailty improved significantly in the intervention arm as compared to the control arm (4.7(4.5–5.0) to 4.2(4.1–4.5), (P < 0.00) vs 4.7(4.6–5.0) to 4.7(4.4–5.2), (P = 0.70) at 6 months. The disease severity as assessed by CTP and MELD, scores showed a significant improvement in the rSMT group as compared to the SMT group (P < 0.05). The delta change in MELD score was −2.3 ± 2.9 versus 1.7 ± 5.4 (P < 0.00) in the intervention arm as compared to control arm. Inflammatory markers showed significant improvement, with a higher delta change in IL-6 in the intervention arm (-10 [-15.7/-4.4] vs -5 [-10.2/-0.5]; P = 0.01). The patients in rSMT arm had lesser number of hospitalizations 8(16%) vs 26(52%); P < 0.00) over the course of 6 months. The mortality in rSMT and SMT arms was 10% (n = 5), and 22% (n = 11), respectively though there was no significant difference in the overall survival (P = 0.11). Conclusion Rifaximin therapy in decompensated cirrhosis has a significant impact on improving frailty and disease severity, with a reduction in hospitalization rate. Clinical Trial Registry Number CTRI/2023/01/048824 Graphical Abstract
- 20 May 2025
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 15 (6) , 102594
Plasma Exchange With Corticosteroids as a Rescue Therapy for Severe Prolonged Cholestasis in Acute Viral Hepatitis
- 20 May 2025
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 15 (6) , 102594
Plasma Exchange With Corticosteroids as a Rescue Therapy for Severe Prolonged Cholestasis in Acute Viral Hepatitis
- 3 January 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (6) , 971-987
Experience With Dabigatran on Rate of Portal Vein Thrombosis Recanalization, Disease Progression and Survival
Background and Aims: We assessed clinical, procoagulant and genetic risk factors and clinical outcomes in dabigatran‐treated patients with non‐tumoural acute and acute‐on‐chronic portal vein thrombosis (PVT).Methods: Patients with a new diagnosis of non‐tumoural acute and acute‐on‐chronic PVT between January 2021 and January 2024 (aged ≥ 18 years) in those without/with cirrhosis (Child‐Pugh (CP)‐A/B/C ≤ 10) were started on dabigatran and followed and compared with those on vitamin K antagonist (VKA) and untreated individuals.Results: Dabigatran was prescribed in 119 patients with PVT type 1 (61, 51.3%), type 2 (34, 28.6%), type 3 (24, 20.2%); 72 (60.5%) with cirrhosis [CP‐A (27, 37.5%), CP‐B (43, 59.7%) and CP‐C10 (2, 2.8%)]. Procoagulant factors noted were JAK2V617F (10.1%), CALR (2.5%) and factor V Leiden (1.6%) mutations, antiphospholipid syndrome (APS, 15.2%), isolated Protein C (14.3%) and Protein S (16.8%) deficiency. Comparators: 28 patients who declined anticoagulation/were unable to come for follow‐up, and six with CP‐C received VKA. Overall recanalization rate (RR) on dabigatran was 56 (47.1%); 25 (21%) complete recanalization, 31 (26%) partial recanalization and 63 (52.9%) stable PVT over median follow‐up of 32 months. Patients not anticoagulated had a spontaneous RR in 21.4% (28 patients; p = 0.005 compared with dabigatran group) and none recanalized on VKA. On multivariable analysis, predictors of recanalization on dabigatran were Factor VIII Antigen level (FVIII:Ag, HR 0.6; 95% CI 0.3–0.9, p = 0.032), non‐occlusive PVT (HR 3.5, 95% CI 1.9–5.6, p = 0.025) and acute PVT (HR 2.1; 95% CI 1.5–3.2, p = 0.003). Mortality was 14 (11.8%).Conclusion: On dabigatran, 47% of 119 patients achieved portal vein recanalization over 32 months of follow‐up which was higher than the spontaneous RR (21.4%) in an untreated cohort. High Factor VIII:Ag was a predictor of non‐recanalization. Dabigatran was safe in cirrhosis (CP‐A and B) while further work is needed in CP‐C.
- 3 January 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (6) , 971-987
Experience With Dabigatran on Rate of Portal Vein Thrombosis Recanalization, Disease Progression and Survival
Background and Aims: We assessed clinical, procoagulant and genetic risk factors and clinical outcomes in dabigatran‐treated patients with non‐tumoural acute and acute‐on‐chronic portal vein thrombosis (PVT).Methods: Patients with a new diagnosis of non‐tumoural acute and acute‐on‐chronic PVT between January 2021 and January 2024 (aged ≥ 18 years) in those without/with cirrhosis (Child‐Pugh (CP)‐A/B/C ≤ 10) were started on dabigatran and followed and compared with those on vitamin K antagonist (VKA) and untreated individuals.Results: Dabigatran was prescribed in 119 patients with PVT type 1 (61, 51.3%), type 2 (34, 28.6%), type 3 (24, 20.2%); 72 (60.5%) with cirrhosis [CP‐A (27, 37.5%), CP‐B (43, 59.7%) and CP‐C10 (2, 2.8%)]. Procoagulant factors noted were JAK2V617F (10.1%), CALR (2.5%) and factor V Leiden (1.6%) mutations, antiphospholipid syndrome (APS, 15.2%), isolated Protein C (14.3%) and Protein S (16.8%) deficiency. Comparators: 28 patients who declined anticoagulation/were unable to come for follow‐up, and six with CP‐C received VKA. Overall recanalization rate (RR) on dabigatran was 56 (47.1%); 25 (21%) complete recanalization, 31 (26%) partial recanalization and 63 (52.9%) stable PVT over median follow‐up of 32 months. Patients not anticoagulated had a spontaneous RR in 21.4% (28 patients; p = 0.005 compared with dabigatran group) and none recanalized on VKA. On multivariable analysis, predictors of recanalization on dabigatran were Factor VIII Antigen level (FVIII:Ag, HR 0.6; 95% CI 0.3–0.9, p = 0.032), non‐occlusive PVT (HR 3.5, 95% CI 1.9–5.6, p = 0.025) and acute PVT (HR 2.1; 95% CI 1.5–3.2, p = 0.003). Mortality was 14 (11.8%).Conclusion: On dabigatran, 47% of 119 patients achieved portal vein recanalization over 32 months of follow‐up which was higher than the spontaneous RR (21.4%) in an untreated cohort. High Factor VIII:Ag was a predictor of non‐recanalization. Dabigatran was safe in cirrhosis (CP‐A and B) while further work is needed in CP‐C.
- 23 September 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 60 (11-12) , 1534-1548
Identification of four novel acute‐on‐chronic liver failure clusters with distinct clinical trajectories and mortality using machine learning methods
Summary: Background and Aims: Machine learning (ML) can identify the hidden patterns without hypothesis in heterogeneous diseases like acute‐on‐chronic live failure (ACLF). We employed ML to describe and predict yet unknown clusters in ACLF.Methods: Clinical data of 1568 patients with ACLF from a tertiary care centre (2015–2023) were subjected to distance‐, density‐ and model‐based clustering algorithms. Final model was selected on best cluster separation, viz. Silhouette width and Dunn's index (for distance‐ or density‐based algorithms) and minimum BIC (for model‐based algorithms). Cluster assignments, patient trajectories and survival were analysed through inferential statistics. Supervised ML models were trained in 70% data that predicted clusters in remaining 30% data followed by an temporal validation.Results: The cohort was male‐predominant (87%), aged 44.3 years, with alcohol‐associated hepatitis (62.9%) and survival of 50.5%. Due to poor performance of distance‐ and density‐based algorithms and better explainability, the latent class model (LCM) was selected for exploration. LCM revealed four clusters with distinct trajectories, reversibility and survival (independent of MELD, CLIF‐C ACLF and AARC scores). Cluster1 had patients with none/one organ failure and highest reversibility. Cluster2 had females with viral hepatitis and two organ failures. More‐than‐one acute precipitant, severity, infections, organ failures and irreversibility escalated from clusters 1 to 4. Circulatory and renal failures critically influenced cluster assignments. Incorporating clusters to CLIF‐C ACLF, infection and ACLF definition improved the discriminative accuracy of CLIF‐C‐ACLF by 11%. Extreme gradient boost and decision trees could predict clusters with AUCs of 0.989 (0.979–0.995) and 0.875 (0.865–0.890). MELD, CLIF‐C‐OF, haemoglobin, lactate, CLIF‐C‐ACLF and ALT were critical variables for cluster prediction. Clusters with distinct survival were documented in a temporal validation cohort.Conclusions: ML for the first time could identify clusters with distinct phenotypes, trajectories and outcomes in ACLF. Stratification into clusters can address heterogeneity, guide prognosis, recruitment in trials, resource allocation and liver transplant discussions in ACLF.
- 23 September 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 60 (11-12) , 1534-1548
Identification of four novel acute‐on‐chronic liver failure clusters with distinct clinical trajectories and mortality using machine learning methods
Summary: Background and Aims: Machine learning (ML) can identify the hidden patterns without hypothesis in heterogeneous diseases like acute‐on‐chronic live failure (ACLF). We employed ML to describe and predict yet unknown clusters in ACLF.Methods: Clinical data of 1568 patients with ACLF from a tertiary care centre (2015–2023) were subjected to distance‐, density‐ and model‐based clustering algorithms. Final model was selected on best cluster separation, viz. Silhouette width and Dunn's index (for distance‐ or density‐based algorithms) and minimum BIC (for model‐based algorithms). Cluster assignments, patient trajectories and survival were analysed through inferential statistics. Supervised ML models were trained in 70% data that predicted clusters in remaining 30% data followed by an temporal validation.Results: The cohort was male‐predominant (87%), aged 44.3 years, with alcohol‐associated hepatitis (62.9%) and survival of 50.5%. Due to poor performance of distance‐ and density‐based algorithms and better explainability, the latent class model (LCM) was selected for exploration. LCM revealed four clusters with distinct trajectories, reversibility and survival (independent of MELD, CLIF‐C ACLF and AARC scores). Cluster1 had patients with none/one organ failure and highest reversibility. Cluster2 had females with viral hepatitis and two organ failures. More‐than‐one acute precipitant, severity, infections, organ failures and irreversibility escalated from clusters 1 to 4. Circulatory and renal failures critically influenced cluster assignments. Incorporating clusters to CLIF‐C ACLF, infection and ACLF definition improved the discriminative accuracy of CLIF‐C‐ACLF by 11%. Extreme gradient boost and decision trees could predict clusters with AUCs of 0.989 (0.979–0.995) and 0.875 (0.865–0.890). MELD, CLIF‐C‐OF, haemoglobin, lactate, CLIF‐C‐ACLF and ALT were critical variables for cluster prediction. Clusters with distinct survival were documented in a temporal validation cohort.Conclusions: ML for the first time could identify clusters with distinct phenotypes, trajectories and outcomes in ACLF. Stratification into clusters can address heterogeneity, guide prognosis, recruitment in trials, resource allocation and liver transplant discussions in ACLF.
- 12 August 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 60 (8) , 1005-1020
Myokines are associated with progression, course and mortality in alcohol‐associated liver disease
Summary: Background and Aims: Myokines are the muscle‐derived hormones orchestrating muscle and systemic health. Their role in the progression of alcohol‐associated liver disease (ALD) remains elusive.Methods: Three‐hundred‐one patients across the spectrum of ALD including fatty liver (FL, N = 13), compensated cirrhosis (CC, N = 17), non‐acute decompensation (NAD, N = 95), acute decompensation (AD, N = 51) and acute‐on‐chronic liver failure (ACLF, N = 125) were recruited between 2021 and 2023. Plasma myostatin, decorin levels, nutritional status, handgrip strength (HGS), systemic inflammation, infection, ammonia, disease course and 30‐day mortality were recorded.Results: Patients aged 48 years (IQR: 38–52) and 97.7% of males were enrolled. Myostatin was elevated while decorin was reduced in cirrhosis compared to without cirrhosis, and further in DC compared to CC (p < 0.001). A step‐wise increase in myostatin and reduction in decorin was observed transitioning from NAD to AD to ACLF (p < 0.001). Myostatin was further increased and decorin was reduced along with the grades and organ failures in AD and ACLF (p < 0.001, each). Baseline decorin (AUC: 0.797) and its combination with MELD (AUC: 0.814) predicted disease resolution in AD and ACLF. Although, both myostatin (aOR: 18.96) and decorin (aOR: 0.02) could predict mortality, decorin was independent (aOR: 0.04) and additive to MELD (AUC of MELD+logDecorin + logTLC + HE‐grade:0.815); p < 0.05 each. Myostatin increased and decorin reduced with inflammation, hyperammonaemia, malnutrition and HGS in AD and ACLF (p < 0.05, each).Conclusion: Myokines are linked with malnutrition, fibrosis, systemic inflammation, organ failures, disease course and mortality in ALD. Decorin enhances the risk estimation of mortality of MELD in AD and ACLF. Therapeutic modulation of myokines is a potentially disease‐modifying target in ALD.
- 12 August 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 60 (8) , 1005-1020
Myokines are associated with progression, course and mortality in alcohol‐associated liver disease
Summary: Background and Aims: Myokines are the muscle‐derived hormones orchestrating muscle and systemic health. Their role in the progression of alcohol‐associated liver disease (ALD) remains elusive.Methods: Three‐hundred‐one patients across the spectrum of ALD including fatty liver (FL, N = 13), compensated cirrhosis (CC, N = 17), non‐acute decompensation (NAD, N = 95), acute decompensation (AD, N = 51) and acute‐on‐chronic liver failure (ACLF, N = 125) were recruited between 2021 and 2023. Plasma myostatin, decorin levels, nutritional status, handgrip strength (HGS), systemic inflammation, infection, ammonia, disease course and 30‐day mortality were recorded.Results: Patients aged 48 years (IQR: 38–52) and 97.7% of males were enrolled. Myostatin was elevated while decorin was reduced in cirrhosis compared to without cirrhosis, and further in DC compared to CC (p < 0.001). A step‐wise increase in myostatin and reduction in decorin was observed transitioning from NAD to AD to ACLF (p < 0.001). Myostatin was further increased and decorin was reduced along with the grades and organ failures in AD and ACLF (p < 0.001, each). Baseline decorin (AUC: 0.797) and its combination with MELD (AUC: 0.814) predicted disease resolution in AD and ACLF. Although, both myostatin (aOR: 18.96) and decorin (aOR: 0.02) could predict mortality, decorin was independent (aOR: 0.04) and additive to MELD (AUC of MELD+logDecorin + logTLC + HE‐grade:0.815); p < 0.05 each. Myostatin increased and decorin reduced with inflammation, hyperammonaemia, malnutrition and HGS in AD and ACLF (p < 0.05, each).Conclusion: Myokines are linked with malnutrition, fibrosis, systemic inflammation, organ failures, disease course and mortality in ALD. Decorin enhances the risk estimation of mortality of MELD in AD and ACLF. Therapeutic modulation of myokines is a potentially disease‐modifying target in ALD.
- 10 August 2024
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 15 (1) , 102400
Central Obesity is an Independent Determinant of Advanced Fibrosis in Lean Patients With Nonalcoholic Fatty Liver Disease
- 10 August 2024
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 15 (1) , 102400
Central Obesity is an Independent Determinant of Advanced Fibrosis in Lean Patients With Nonalcoholic Fatty Liver Disease
- 22 May 2024
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 14 (6) , 101432
Recurrence of Primary Disease After Adult Liver Transplant – Risk Factors, Early Diagnosis, Management, and Prevention
- 22 May 2024
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 14 (6) , 101432
Recurrence of Primary Disease After Adult Liver Transplant – Risk Factors, Early Diagnosis, Management, and Prevention
- 26 April 2024
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 14 (5) , 101438
Endoscopic Ultrasound Guided Radiofrequency Ablation for Caudate Lobe Hepatocellular Carcinoma: A New Paradigm in Endohepatology
- 26 April 2024
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 14 (5) , 101438
Endoscopic Ultrasound Guided Radiofrequency Ablation for Caudate Lobe Hepatocellular Carcinoma: A New Paradigm in Endohepatology
- 13 March 2024
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 14 (5) , 101394
Endoscopic Ultrasound Bubble Study for Detection of Extracardiac Shunting: Endohepatology in the Diagnosis of Hepatopulmonary Syndrome
- 13 March 2024
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 14 (5) , 101394
Endoscopic Ultrasound Bubble Study for Detection of Extracardiac Shunting: Endohepatology in the Diagnosis of Hepatopulmonary Syndrome
- 20 February 2024
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 14 (4) , 101373
Prevalence of Frailty and Its Impact on Mortality and Hospitalization in Patients With Cirrhosis: A Systematic Review and Meta-analysis
- 20 February 2024
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 14 (4) , 101373
Prevalence of Frailty and Its Impact on Mortality and Hospitalization in Patients With Cirrhosis: A Systematic Review and Meta-analysis